In a big boost to Eisai and partner Biogen, the US Department of Veterans Affairs has agreed to cover their new amyloid-busting Alzheimer’s disease therapy Leqembi, becomi
Eisai and partner Biogen have edged closer to a full FDA approval of their Alzheimer’s disease therapy Leqembi, after the US regulator set a 6th July date for their market
Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group
The US Centers for Medicare and Medicaid Services (CMS) has rejected broader coverage of new amyloid-targeting Alzheimer’s disease treatments, a decision branded “pernicio
Eisai didn't reveal sales of its new Alzheimer's disease therapy Leqembi in its third-quarter update, but said the launch was running "ahead of expectations" since the dru
Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track
Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod